{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:01:01Z","timestamp":1782471661829,"version":"3.54.5"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1168954"],"award-info":[{"award-number":["APP1168954"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A precipitous decline in health status among people recently released from prison is common. In Victoria, Australia, opioid agonist treatment (OAT) in the community involves frequent contact with primary care, potentially facilitating broader use of primary healthcare services. Among a cohort of men who injected drugs regularly pre-imprisonment, we estimated differences in rates of primary healthcare use and medication dispensation between people who did and did not receive OAT post-release.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data came from the Prison and Transition Health Cohort Study. Three-month post-release follow-up interviews were linked with primary care and medication dispensation records. Generalised linear models were fit with one exposure (OAT: none\/partial\/complete) for 13 outcomes relating to primary healthcare use, pathology testing, and medication dispensation, adjusted for other covariates. Coefficients were reported as adjusted incidence rate ratios (AIRR).\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Analyses included 255 participants. Compared to no OAT use, both partial and complete OAT use were associated with increased rates of standard (AIRR: 3.02, 95%CI: 1.88\u20134.86; AIRR: 3.66, 95%CI: 2.57\u20135.23), extended (AIRR: 2.56, 95%CI: 1.41\u20134.67; AIRR: 2.55, 95%CI: 1.60\u20134.07) and mental health-related (AIRR: 2.71, 95%CI: 1.42\u20135.20; AIRR: 2.27, 95%CI: 1.33\u20133.87) general practitioner (GP) consultations, total medication (AIRR: 1.88, 95%CI: 1.19\u20132.98; AIRR: 2.40, 95%CI: 1.71\u20133.37), benzodiazepine (AIRR: 4.99, 95%CI: 2.81\u20138.85; AIRR: 8.30, 95%CI: 5.28\u201313.04) and gabapentinoid (AIRR: 6.78, 95%CI: 3.34\u201313.77; AIRR: 4.34, 95%CI: 2.37\u20137.94) dispensations, respectively. Partial OAT use was also associated with increased after-hours GP consultations (AIRR: 4.61, 95%CI: 2.24\u20139.48) and complete OAT use? with increased pathology utilisation (e.g. haematological, chemical, microbiological or immunological tissue\/sample testing; AIRR: 2.30, 95%CI: 1.52\u20133.48).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We observed higher rates of primary healthcare use and medication dispensation among people who reported partial and complete OAT use post-release. Findings suggest that access to OAT post-release may have a collateral benefit in supporting broader health service utilisation, underscoring the importance of retention in OAT after release from prison.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-023-00773-2","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T14:02:59Z","timestamp":1680012179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Michael","family":"Curtis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dietze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh C.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart A.","family":"Kinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Campbell","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley J.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reece D.","family":"Cossar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stoov\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"issue":"9769","key":"773_CR1","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(10)61053-7","volume":"377","author":"S Fazel","year":"2011","unstructured":"Fazel S, Baillargeon J. The health of prisoners. Lancet. 2011;377(9769):956\u201365.","journal-title":"Lancet"},{"issue":"1","key":"773_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/epirev\/mxx018","volume":"40","author":"SA Kinner","year":"2018","unstructured":"Kinner SA, Young JT. Understanding and improving the health of people who experience incarceration: an overview and synthesis. Epidemiol Rev. 2018;40(1):4\u201311.","journal-title":"Epidemiol Rev"},{"issue":"10","key":"773_CR3","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1111\/add.13877","volume":"112","author":"S Fazel","year":"2017","unstructured":"Fazel S, Yoon IA, Hayes AJ. Substance use disorders in prisoners: an updated systematic review and meta-regression analysis in recently incarcerated men and women. Addiction. 2017;112(10):1725\u201339.","journal-title":"Addiction"},{"issue":"9","key":"773_CR4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S2215-0366(16)30142-0","volume":"3","author":"S Fazel","year":"2016","unstructured":"Fazel S, et al. Mental health of prisoners: prevalence, adverse outcomes, and interventions. Lancet Psychiatry. 2016;3(9):871\u201381.","journal-title":"Lancet Psychiatry"},{"key":"773_CR5","doi-asserted-by":"crossref","unstructured":"Australian Institute of Health and Welfare, The health of Australia's prisoners 2018. 2019, Australian Institute of Health and Welfare: Canberra.","DOI":"10.21820\/23987073.2018.2.80"},{"issue":"4","key":"773_CR6","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/hep.26387","volume":"58","author":"S Larney","year":"2013","unstructured":"Larney S, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013;58(4):1215\u201324.","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"773_CR7","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.drugpo.2014.10.012","volume":"26","author":"K Dolan","year":"2015","unstructured":"Dolan K, et al. People who inject drugs in prison: HIV prevalence, transmission and prevention. Int J Drug Policy. 2015;26(Suppl 1):S12\u20135.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"773_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1375\/acri.39.1.20","volume":"39","author":"E Baldry","year":"2016","unstructured":"Baldry E, et al. Ex-prisoners, homelessness and the state in Australia. Aust N Z J Criminol. 2016;39(1):20\u201333.","journal-title":"Aust N Z J Criminol"},{"issue":"1","key":"773_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0306624X14548023","volume":"60","author":"D Wallace","year":"2016","unstructured":"Wallace D, et al. Examining the role of familial support during prison and after release on post-incarceration mental health. Int J Offender Ther Comp Criminol. 2016;60(1):3\u201320.","journal-title":"Int J Offender Ther Comp Criminol"},{"key":"773_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.drugalcdep.2016.08.640","volume":"168","author":"RJ Winter","year":"2016","unstructured":"Winter RJ, et al. Resumption of injecting drug use following release from prison in Australia. Drug Alcohol Depend. 2016;168:104\u201311.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"773_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13722-019-0136-6","volume":"14","author":"A Chamberlain","year":"2019","unstructured":"Chamberlain A, et al. Illicit substance use after release from prison among formerly incarcerated primary care patients: a cross-sectional study. Addict Sci Clin Pract. 2019;14(1):7.","journal-title":"Addict Sci Clin Pract"},{"issue":"11","key":"773_CR12","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1111\/add.15971","volume":"117","author":"M Curtis","year":"2022","unstructured":"Curtis M, et al. High rates of resumption of injecting drug use following release from prison among men who injected drugs before imprisonment. Addiction. 2022;117(11):2887\u201398.","journal-title":"Addiction"},{"issue":"5","key":"773_CR13","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1086\/681301","volume":"120","author":"B Western","year":"2015","unstructured":"Western B, et al. Stress and hardship after prison. Am J Sociol. 2015;120(5):1512\u201347.","journal-title":"Am J Sociol"},{"key":"773_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108970","volume":"227","author":"AC Stewart","year":"2021","unstructured":"Stewart AC, et al. The prison and transition health (PATH) cohort study: prevalence of health, social, and crime characteristics after release from prison for men reporting a history of injecting drug use in Victoria Australia. Drug Alcohol Depend. 2021;227: 108970.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"773_CR15","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1080\/07418825.2010.535553","volume":"28","author":"CA Visher","year":"2010","unstructured":"Visher CA, Debus-Sherrill SA, Yahner J. Employment after prison: a longitudinal study of former prisoners. Justice Q. 2010;28(5):698\u2013718.","journal-title":"Justice Q"},{"key":"773_CR16","doi-asserted-by":"publisher","first-page":"103571","DOI":"10.1016\/j.drugpo.2021.103571","volume":"101","author":"SE Schroeder","year":"2022","unstructured":"Schroeder SE, et al. \u201cIt\u2019s a revolving door\u201d: ego-depletion among prisoners with injecting drug use histories as a barrier to post-release success. Int J Drug Policy. 2022;101:103571.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"773_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/0004865815620703","volume":"50","author":"M Denton","year":"2016","unstructured":"Denton M, Foster M, Bland R. How the prison-to-community transition risk environment influences the experience of men with co-occurring mental health and substance use disorder. Aust N Z J Criminol. 2016;50(1):39\u201355.","journal-title":"Aust N Z J Criminol"},{"issue":"1","key":"773_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2194-7899-1-3","volume":"1","author":"L Brinkley-Rubinstein","year":"2013","unstructured":"Brinkley-Rubinstein L. Incarceration as a catalyst for worsening health. Health Justice. 2013;1(1):3.","journal-title":"Health Justice"},{"issue":"10","key":"773_CR19","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1136\/jech-2014-204295","volume":"68","author":"MJ Spittal","year":"2014","unstructured":"Spittal MJ, et al. Suicide in adults released from prison in Queensland, Australia: a cohort study. J Epidemiol Community Health. 2014;68(10):993\u20138.","journal-title":"J Epidemiol Community Health"},{"issue":"9","key":"773_CR20","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/j.1360-0443.2010.02990.x","volume":"105","author":"EL Merrall","year":"2010","unstructured":"Merrall EL, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105(9):1545\u201354.","journal-title":"Addiction"},{"issue":"8","key":"773_CR21","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/add.13803","volume":"112","author":"A Bukten","year":"2017","unstructured":"Bukten A, et al. High risk of overdose death following release from prison: variations in mortality during a 15-year observation period. Addiction. 2017;112(8):1432\u20139.","journal-title":"Addiction"},{"issue":"6","key":"773_CR22","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1177\/1039856215613008","volume":"23","author":"SA Kinner","year":"2015","unstructured":"Kinner SA, Young JT, Carroll M. The pivotal role of primary care in meeting the health needs of people recently released from prison. Australas Psychiatry. 2015;23(6):650\u20133.","journal-title":"Australas Psychiatry"},{"issue":"2","key":"773_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/cbm.2106","volume":"29","author":"DF de Andrade","year":"2019","unstructured":"de Andrade DF, et al. Emergency health service contact and reincarceration after release from prison: a prospective cohort study. Crim Behav Ment Health. 2019;29(2):85\u201393.","journal-title":"Crim Behav Ment Health"},{"issue":"2","key":"773_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5694\/mja16.00841","volume":"207","author":"M Carroll","year":"2017","unstructured":"Carroll M, et al. High rates of general practice attendance by former prisoners: a prospective cohort study. Med J Aust. 2017;207(2):75\u201380.","journal-title":"Med J Aust"},{"issue":"6","key":"773_CR25","doi-asserted-by":"publisher","first-page":"e008021","DOI":"10.1136\/bmjopen-2015-008021","volume":"5","author":"JT Young","year":"2015","unstructured":"Young JT, et al. Early primary care physician contact and health service utilisation in a large sample of recently released ex-prisoners in Australia: prospective cohort study. BMJ Open. 2015;5(6):e008021.","journal-title":"BMJ Open"},{"key":"773_CR26","unstructured":"Justice Health, Victorian Prison Opioid Substitution Therapy Program Guidelines Department of Justice & Regulation, Editor. 2015, Victorian Government: Melbourne."},{"key":"773_CR27","unstructured":"Department of Health and Human Services, Policy for maintenance pharmacotherapy for opioid dependence, D.o.H.a.H. Services, Editor. 2016, Victorian Government: Melbourne."},{"key":"773_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jsat.2016.05.002","volume":"67","author":"MK Mohlman","year":"2016","unstructured":"Mohlman MK, et al. Impact of medication-assisted treatment for opioid addiction on medicaid expenditures and health services utilization rates in vermont. J Subst Abuse Treat. 2016;67:9\u201314.","journal-title":"J Subst Abuse Treat"},{"key":"773_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/SAR.S150253","volume":"9","author":"NA Ronquest","year":"2018","unstructured":"Ronquest NA, et al. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. Subst Abuse Rehabil. 2018;9:59\u201378.","journal-title":"Subst Abuse Rehabil"},{"issue":"4","key":"773_CR30","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1080\/13696998.2018.1427101","volume":"21","author":"A Shah","year":"2018","unstructured":"Shah A, et al. Healthcare utilization and costs associated with treatment for opioid dependence. J Med Econ. 2018;21(4):406\u201315.","journal-title":"J Med Econ"},{"issue":"5","key":"773_CR31","first-page":"343","volume":"65","author":"S Spithoff","year":"2019","unstructured":"Spithoff S, et al. Quality of primary care among individuals receiving treatment for opioid use disorder. Can Fam Physician. 2019;65(5):343\u201351.","journal-title":"Can Fam Physician"},{"issue":"4","key":"773_CR32","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jsat.2013.10.014","volume":"46","author":"J Tkacz","year":"2014","unstructured":"Tkacz J, et al. Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. J Subst Abuse Treat. 2014;46(4):456\u201362.","journal-title":"J Subst Abuse Treat"},{"issue":"Suppl 8","key":"773_CR33","first-page":"S235","volume":"17","author":"O Baser","year":"2011","unstructured":"Baser O, et al. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011;17(Suppl 8):S235\u201348.","journal-title":"Am J Manag Care"},{"issue":"1","key":"773_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11524-014-9924-1","volume":"92","author":"MS Haddad","year":"2015","unstructured":"Haddad MS, Zelenev A, Altice FL. Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers. J Urban Health. 2015;92(1):193\u2013213.","journal-title":"J Urban Health"},{"issue":"1","key":"773_CR35","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1093\/cid\/ciaa612","volume":"73","author":"J Grebely","year":"2021","unstructured":"Grebely J, et al. Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: a systematic review and meta-analysis. Clin Infect Dis. 2021;73(1):e107\u201318.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"773_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12954-022-00643-3","volume":"19","author":"J Iversen","year":"2022","unstructured":"Iversen J, et al. Uptake of COVID-19 vaccination among people who inject drugs. Harm Reduct J. 2022;19(1):59.","journal-title":"Harm Reduct J"},{"key":"773_CR37","unstructured":"Ward P, Mattick R. Health care utilisation and costs under the Commonwealth Medicare Benefit Scheme by methadone maintenance patients in NSW. In: NDARC Technical Report No. 240. 2005. Sydney: National Drug and Alcohol Research Centre"},{"key":"773_CR38","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/1472-6963-14-308","volume":"14","author":"D Nambiar","year":"2014","unstructured":"Nambiar D, Stoove M, Dietze P. A cross-sectional study describing factors associated with utilisation of GP services by a cohort of people who inject drugs. BMC Health Serv Res. 2014;14:308.","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"773_CR39","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/jech-2015-206565","volume":"70","author":"SA Kinner","year":"2016","unstructured":"Kinner SA, et al. Low-intensity case management increases contact with primary care in recently released prisoners: a single-blinded, multisite, randomised controlled trial. J Epidemiol Community Health. 2016;70(7):683\u20138.","journal-title":"J Epidemiol Community Health"},{"issue":"5","key":"773_CR40","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/sltb.12639","volume":"50","author":"JT Young","year":"2020","unstructured":"Young JT, et al. Contact with mental health services after acute care for self-harm among adults released from prison: a prospective data linkage study. Suicide Life Threat Behav. 2020;50(5):990\u20131006.","journal-title":"Suicide Life Threat Behav"},{"issue":"6","key":"773_CR41","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1360-0443.2005.01050.x","volume":"100","author":"KA Dolan","year":"2005","unstructured":"Dolan KA, et al. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005;100(6):820\u20138.","journal-title":"Addiction"},{"issue":"8","key":"773_CR42","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1111\/add.12536","volume":"109","author":"L Degenhardt","year":"2014","unstructured":"Degenhardt L, et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction. 2014;109(8):1306\u201317.","journal-title":"Addiction"},{"issue":"2","key":"773_CR43","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1360-0443.2011.03618.x","volume":"107","author":"S Larney","year":"2012","unstructured":"Larney S, et al. Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration. Addiction. 2012;107(2):372\u201380.","journal-title":"Addiction"},{"issue":"8","key":"773_CR44","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1377\/hlthaff.2020.02156","volume":"40","author":"BA Howell","year":"2021","unstructured":"Howell BA, et al. Changes in health services use after receipt of medications for opioid use disorder in a statewide correctional system. Health Aff. 2021;40(8):1304\u201311.","journal-title":"Health Aff"},{"key":"773_CR45","unstructured":"Australian Bureau of Statistics. National, state and territory population. 2021; Available from: https:\/\/www.abs.gov.au\/statistics\/people\/population\/national-state-and-territory-population\/latest-release."},{"key":"773_CR46","unstructured":"Australian Bureau of Statistics, Prisoner numbers and prisoner rates by Indigenous Status and sex, States and territories, 2006\u20132021 (Tables 40 to 42). 2021. Canberra: Australian Bureau of Statistics"},{"key":"773_CR47","unstructured":"Australian Institute of Health and Welfare, National Opioid Pharmacotherapy Statistics Annual Data Collection. 2022. Canberra: AIHW."},{"issue":"3","key":"773_CR48","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s11524-019-00353-5","volume":"96","author":"A Kirwan","year":"2019","unstructured":"Kirwan A, et al. The prison and transition health (PATH) cohort study: study protocol and baseline characteristics of a cohort of men with a history of injecting drug use leaving prison in Australia. J Urban Health. 2019;96(3):400\u201310.","journal-title":"J Urban Health"},{"issue":"1","key":"773_CR49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12874-021-01380-0","volume":"21","author":"AC Stewart","year":"2021","unstructured":"Stewart AC, et al. Strategies to maximise study retention and limit attrition bias in a prospective cohort study of men reporting a history of injecting drug use released from prison: the prison and transition health study. BMC Med Res Methodol. 2021;21(1):185.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"773_CR50","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12874-018-0536-4","volume":"18","author":"H Tibble","year":"2018","unstructured":"Tibble H, et al. The importance of including aliases in data linkage with vulnerable populations. BMC Med Res Methodol. 2018;18(1):76.","journal-title":"BMC Med Res Methodol"},{"key":"773_CR51","unstructured":"Department of Health, Medicare Benefits Schedule Book. 2021. Canberra: Commonwealth of Australia"},{"issue":"1","key":"773_CR52","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1186\/s13104-015-1616-8","volume":"8","author":"L Mellish","year":"2015","unstructured":"Mellish L, et al. The Australian pharmaceutical benefits scheme data collection: a practical guide for researchers. BMC Res Notes. 2015;8(1):634.","journal-title":"BMC Res Notes"},{"key":"773_CR53","unstructured":"Department of Health, PBS Expenditure and prescriptions report 1 July 2020 to 30 June 2021. 2021. Canberra: Department of Health"},{"key":"773_CR54","unstructured":"World Health Organization. Anatomical Therapeutic Chemical (ATC) Classification. 2021; Available from: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification."},{"issue":"5","key":"773_CR55","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/add.14106","volume":"113","author":"SJ Forsyth","year":"2018","unstructured":"Forsyth SJ, et al. Incidence and risk factors for mortality after release from prison in Australia: a prospective cohort study. Addiction. 2018;113(5):937\u201345.","journal-title":"Addiction"},{"issue":"6","key":"773_CR56","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1111\/add.15293","volume":"116","author":"WQ Gan","year":"2021","unstructured":"Gan WQ, et al. Risk of overdose-related death for people with a history of incarceration. Addiction. 2021;116(6):1460\u201371.","journal-title":"Addiction"},{"issue":"7","key":"773_CR57","doi-asserted-by":"publisher","first-page":"e0157512","DOI":"10.1371\/journal.pone.0157512","volume":"11","author":"E Groot","year":"2016","unstructured":"Groot E, et al. Drug toxicity deaths after release from incarceration in Ontario, 2006\u20132013: review of coroner\u2019s cases. PLoS ONE. 2016;11(7):e0157512.","journal-title":"PLoS ONE"},{"issue":"6","key":"773_CR58","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/add.14892","volume":"115","author":"D Lewer","year":"2020","unstructured":"Lewer D, et al. Frequency of health-care utilization by adults who use illicit drugs: a systematic review and meta-analysis. Addiction. 2020;115(6):1011\u201323.","journal-title":"Addiction"},{"issue":"3","key":"773_CR59","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/ADT.0000000000000069","volume":"14","author":"S Darke","year":"2015","unstructured":"Darke S, et al. Health service utilization among heroin users. Addict Disord Treat. 2015;14(3):159\u201366.","journal-title":"Addict Disord Treat"},{"issue":"2","key":"773_CR60","doi-asserted-by":"publisher","first-page":"358","DOI":"10.4081\/gh.2015.358","volume":"10","author":"MR McGrail","year":"2015","unstructured":"McGrail MR, Humphreys JS. Spatial access disparities to primary health care in rural and remote Australia. Geospat Health. 2015;10(2):358.","journal-title":"Geospat Health"},{"key":"773_CR61","unstructured":"Australian Bureau of Statistics. ASGS Coding Indexes (2016). 2016; Available from: https:\/\/data.gov.au\/data\/dataset\/asgs-coding-indexes-2016\/resource\/c6051960-6012-452c-ac68-dba55a1f837a."},{"issue":"2","key":"773_CR62","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1046\/j.1440-1614.2001.00869.x","volume":"35","author":"S Donath","year":"2001","unstructured":"Donath S. The validity of the 12-item general health questionnaire in Australia: a comparison between three scoring methods. Aust N Z J Psychiatry. 2001;35(2):231\u20135.","journal-title":"Aust N Z J Psychiatry"},{"key":"773_CR63","unstructured":"Goldberg D. General health questionnaire (GHQ-12). 1992; Nfer-Nelson: Windsor"},{"issue":"1","key":"773_CR64","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1017\/S0033291796004242","volume":"27","author":"DP Goldberg","year":"1997","unstructured":"Goldberg DP, et al. The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychol Med. 1997;27(1):191\u20137.","journal-title":"Psychol Med"},{"issue":"9","key":"773_CR65","doi-asserted-by":"publisher","first-page":"359","DOI":"10.5694\/mja15.00588","volume":"203","author":"TM Plueckhahn","year":"2015","unstructured":"Plueckhahn TM, et al. Are some more equal than others? Challenging the basis for prisoners\u2019 exclusion from Medicare. Med J Aust. 2015;203(9):359\u201361.","journal-title":"Med J Aust"},{"key":"773_CR66","unstructured":"StataCorp, Stata Statistical Software: Release 14. 2015. College Station: StataCorp LP"},{"issue":"3","key":"773_CR67","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11414-017-9553-z","volume":"44","author":"TR Rieckmann","year":"2017","unstructured":"Rieckmann TR, et al. Treating opioid dependence with buprenorphine in the safety net: critical learning from clinical data. J Behav Health Serv Res. 2017;44(3):351\u201363.","journal-title":"J Behav Health Serv Res"},{"issue":"2","key":"773_CR68","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.drugpo.2011.08.005","volume":"23","author":"MM Islam","year":"2012","unstructured":"Islam MM, et al. The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: a narrative synthesis of literature. Int J Drug Policy. 2012;23(2):94\u2013102.","journal-title":"Int J Drug Policy"},{"key":"773_CR69","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.drugpo.2019.05.023","volume":"72","author":"ME Socias","year":"2019","unstructured":"Socias ME, et al. Integrated models of care for people who inject drugs and live with hepatitis C virus: a systematic review. Int J Drug Policy. 2019;72:146\u201359.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"773_CR70","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1186\/s12913-022-08209-6","volume":"22","author":"L Calais-Ferreira","year":"2022","unstructured":"Calais-Ferreira L, et al. Multimorbidity and quality of primary care after release from prison: a prospective data-linkage cohort study. BMC Health Serv Res. 2022;22(1):876.","journal-title":"BMC Health Serv Res"},{"key":"773_CR71","unstructured":"Medical Board of Australia, Registration Data Table\u2014June 2021. 2021. Melbourne: Medical Board of Australia"},{"key":"773_CR72","unstructured":"Department of Health, Pharmacotherapy training. 2015. Melbourne: Victoria State Government"},{"issue":"11","key":"773_CR73","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5694\/mja2.51095","volume":"214","author":"P Prathivadi","year":"2021","unstructured":"Prathivadi P, Sturgiss EA. When will opioid agonist therapy become a normal part of comprehensive health care? Med J Aust. 2021;214(11):504\u20135.","journal-title":"Med J Aust"},{"issue":"1","key":"773_CR74","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/0976-3147.91934","volume":"3","author":"PJ Whelan","year":"2012","unstructured":"Whelan PJ, Remski K. Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds. J Neurosci Rural Pract. 2012;3(1):45\u201350.","journal-title":"J Neurosci Rural Pract"},{"issue":"3","key":"773_CR75","first-page":"CD002209","volume":"2009","author":"RP Mattick","year":"2009","unstructured":"Mattick RP, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;2009(3):CD002209.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"773_CR76","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jsat.2009.03.002","volume":"37","author":"TW Kinlock","year":"2009","unstructured":"Kinlock TW, et al. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat. 2009;37(3):277\u201385.","journal-title":"J Subst Abuse Treat"},{"key":"773_CR77","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.drugalcdep.2017.11.023","volume":"184","author":"L Brinkley-Rubinstein","year":"2018","unstructured":"Brinkley-Rubinstein L, et al. A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: findings at 12 months post-release. Drug Alcohol Depend. 2018;184:57\u201363.","journal-title":"Drug Alcohol Depend"},{"key":"773_CR78","doi-asserted-by":"publisher","first-page":"109730","DOI":"10.1016\/j.drugalcdep.2022.109730","volume":"242","author":"M Curtis","year":"2023","unstructured":"Curtis M, et al. Discontinuation of opioid agonist treatment following release from prison in a cohort of men who injected drugs prior to imprisonment in Victoria, Australia: a discrete-time survival analysis. Drug Alcohol Depend. 2023;242:109730.","journal-title":"Drug Alcohol Depend"},{"key":"773_CR79","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1747-597X-9-32","volume":"9","author":"A Shepherd","year":"2014","unstructured":"Shepherd A, Perrella B, Hattingh HL. The impact of dispensing fees on compliance with opioid substitution therapy: a mixed methods study. Subst Abuse Treat Prev Policy. 2014;9:32.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"773_CR80","doi-asserted-by":"publisher","first-page":"103472","DOI":"10.1016\/j.drugpo.2021.103472","volume":"99","author":"AD Tran","year":"2022","unstructured":"Tran AD, et al. Economic analysis of out-of-pocket costs among people in opioid agonist treatment: a cross-sectional survey in three Australian jurisdictions. Int J Drug Policy. 2022;99:103472.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"773_CR81","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/dar.13437","volume":"41","author":"E Zahra","year":"2022","unstructured":"Zahra E, et al. Examining the cost and impact of dosing fees among clients in opioid agonist treatment: results from a cross-sectional survey of Australian treatment clients. Drug Alcohol Rev. 2022;41(4):841\u201350.","journal-title":"Drug Alcohol Rev"},{"issue":"7","key":"773_CR82","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1465-3362.2012.00472.x","volume":"31","author":"J Chalmers","year":"2012","unstructured":"Chalmers J, Ritter A. Subsidising patient dispensing fees: the cost of injecting equity into the opioid pharmacotherapy maintenance system. Drug Alcohol Rev. 2012;31(7):911\u20137.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"773_CR83","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1192\/bjp.bp.106.026112","volume":"191","author":"C Haasen","year":"2007","unstructured":"Haasen C, et al. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2007;191(1):55\u201362.","journal-title":"Br J Psychiatry"},{"issue":"Suppl 2","key":"773_CR84","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/S0924-977X(10)70001-8","volume":"20","author":"P Blanken","year":"2010","unstructured":"Blanken P, et al. Heroin-assisted treatment in the Netherlands: history, findings, and international context. Eur Neuropsychopharmacol. 2010;20(Suppl 2):S105\u201358.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"773_CR85","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s11524-007-9198-y","volume":"84","author":"B Fischer","year":"2007","unstructured":"Fischer B, et al. Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics. J Urban Health. 2007;84(4):552\u201362.","journal-title":"J Urban Health"},{"issue":"1","key":"773_CR86","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12911-021-01692-7","volume":"21","author":"MM Hasan","year":"2021","unstructured":"Hasan MM, et al. A machine learning based two-stage clinical decision support system for predicting patients\u2019 discontinuation from opioid use disorder treatment: retrospective observational study. BMC Med Inform Decis Mak. 2021;21(1):331.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"773_CR87","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13722-018-0122-4","volume":"13","author":"Z Schuman-Olivier","year":"2018","unstructured":"Schuman-Olivier Z, et al. MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine\/naloxone adherence during opioid use disorder treatment: a pilot study. Addict Sci Clin Pract. 2018;13(1):21.","journal-title":"Addict Sci Clin Pract"},{"issue":"2","key":"773_CR88","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/03007995.2020.1846022","volume":"37","author":"YA Maricich","year":"2021","unstructured":"Maricich YA, et al. Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder. Curr Med Res Opin. 2021;37(2):167\u201373.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"773_CR89","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1037\/a0037496","volume":"82","author":"DR Christensen","year":"2014","unstructured":"Christensen DR, et al. Adding an Internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014;82(6):964\u201372.","journal-title":"J Consult Clin Psychol"},{"issue":"3","key":"773_CR90","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1071\/AH16007","volume":"41","author":"P Abbott","year":"2017","unstructured":"Abbott P, et al. Supporting continuity of care between prison and the community for women in prison: a medical record review. Aust Health Rev. 2017;41(3):268\u201376.","journal-title":"Aust Health Rev"},{"key":"773_CR91","doi-asserted-by":"publisher","first-page":"94","DOI":"10.5694\/mja2.51774","volume":"218","author":"M Curtis","year":"2022","unstructured":"Curtis M, et al. Non-fatal opioid overdose after release from prison among men who injected drugs prior to their imprisonment: a prospective data linkage study. Med J Aust. 2022;218:94.","journal-title":"Med J Aust"},{"key":"773_CR92","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.02.033","volume":"200","author":"VR Votaw","year":"2019","unstructured":"Votaw VR, et al. The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend. 2019;200:95\u2013114.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"773_CR93","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1016\/S2468-2667(21)00007-4","volume":"6","author":"C Keen","year":"2021","unstructured":"Keen C, et al. Periods of altered risk for non-fatal drug overdose: a self-controlled case series. Lancet Public Health. 2021;6(4):e249\u201359.","journal-title":"Lancet Public Health"},{"issue":"1","key":"773_CR94","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","volume":"81","author":"KE Evoy","year":"2021","unstructured":"Evoy KE, et al. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs. 2021;81(1):125\u201356.","journal-title":"Drugs"},{"issue":"10","key":"773_CR95","doi-asserted-by":"publisher","first-page":"e1002396","DOI":"10.1371\/journal.pmed.1002396","volume":"14","author":"T Gomes","year":"2017","unstructured":"Gomes T, et al. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017;14(10):e1002396.","journal-title":"PLoS Med"},{"issue":"9","key":"773_CR96","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"T Santo Jr","year":"2021","unstructured":"Santo T Jr, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiat. 2021;78(9):979\u201393.","journal-title":"JAMA Psychiat"},{"issue":"10","key":"773_CR97","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1111\/add.12969","volume":"110","author":"SM Bird","year":"2015","unstructured":"Bird SM, et al. Impact of opioid substitution therapy for Scotland\u2019s prisoners on drug-related deaths soon after prisoner release. Addiction. 2015;110(10):1617\u201324.","journal-title":"Addiction"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00773-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-023-00773-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00773-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T14:05:42Z","timestamp":1680012342000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-023-00773-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["773"],"URL":"https:\/\/doi.org\/10.1186\/s12954-023-00773-2","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"assertion":[{"value":"11 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approvals for the Prison and Transition Health Cohort Study were obtained from the Alfred Hospital Ethics Committee (79\/12) DJCS (CF\/14\/10169) and AIHW Ethics Committee (EO2014\/1\/77). All study participants provided consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All study participants provided consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PD has received investigator-driven funding from Gilead Sciences for work related to hepatitis C treatment and an untied educational grant from Indivior for work related to the introduction of buprenorphine\/naloxone into Australia. He has also served as an unpaid member of an Advisory Board for an intranasal naloxone product. The remaining authors declare that they have no conflicts of interest. MS has received investigator-initiated funding from Gilead Sciences, AbbVie and Bristol Myers Squibb, and consultant fees from Gilead Sciences for activities unrelated to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}